EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

31 July 2020
EMA/CHMP/358247/2020 corr.
EMEA/H/C/003932

Public statement

Zurampic

Withdrawal of the marketing authorisation in the European Union

On 31 July 2020, the European Commission issued a notification that the marketing authorisation for Zurampic (lesinurad) in the European Union (EU) had been withdrawn. The withdrawal was at the request of the marketing authorisation holder, Grunenthal GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Zurampic was granted marketing authorisation in the EU on 18 February 2016 for treatment of hyperuricaemia. The marketing authorisation was initially valid for a 5-year period.

The European Public Assessment Report (EPAR) for Zurampic has been updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000